Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT02855944IIIRecurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy)ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCO, GAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitorApproved in Ovarian Cancer
NCT01851369IIAdvanced solid tumors and granulosa cell ovarian cancer (in expansion)A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and LymphomasMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MethoxyamineTRC102Base excision repair inhibitorClinical Trials
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agentApproved in Other Cancers
NCT02873962IIPlatinum resistant or partially sensitive ovarian cancerA Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal CancerMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitorApproved in Ovarian Cancer
NCT02571725IIRecurrent ovarian cancer with germline BRCA1/2 mutations (no prior anti-CTLA-4 mAb)A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian CancerFL, NM, OH, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cellsClinical Trials
NCT02843165IIAdvanced solid tumors with lesion treatable with radiation therapyRandomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic DiseaseCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyRadiotherapy, Irradiation
NCT03428802IIAdvanced solid tumors with POLE, POLD, or BRCA1/2 mutationsA Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic InstabilityNJView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03462342IIRecurrent ovarian cancerCombination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibAZD6738, ATR kinase inhibitor AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03570619IIAdvanced solid tumors with CDK12 alterationsIMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 MutationsFL, MD, MI, MO, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03565991IIAdvanced solid tumors with BRCA1/2 or ATM mutationsA Phase 2 Study To Evaluate Safety And Anti-tumor Activity Of Avelumab In Combination With Talazoparib In Patients With Brca Or Atm Mutant TumorsCA, GA, LA, MA, MO, NJ, NY, OH, OK, PA, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
TalazoparibTalazoparib Tosylate, BMN-673, MDV3800PARP inhibitorApproved in Other Cancers
NCT03579316IIRecurrent ovarian cancer with progression on or after prior PARP inhibitorA Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Ovarian Cancer Patients Who Have Progressed During PARP InhibitionMA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT01876511IIAdvanced solid tumors with positive MSI or tumors with negative MSI and high TMBPhase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) TumorsCA, MD, NY, OH, OR, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03651271IIRecurrent ovarian cancer with high MSIAn Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic CancerCA, MA, NY, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03610490IIRecurrent or refractory high grade serous ovarian cancer or carcinosarcomaClinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MDA-TILautologous tumor-infiltrating lymphocytes MDA-TILAnti-tumor immune responseClinical Trials
NCT03693014IIAdvanced solid tumors with limited progression on checkpoint inhibitor treatmentA Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint BlockadeNJ, NYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyRadiotherapy, Irradiation
NCT03732950IIRecurrent ovarian cancerA Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression ProfilingCA, MNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03734692IIPlatinum sensitive ovarian cancer with first or second recurrence in peritoneal cavitySystemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian CancerPAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RintatolimodAtvogenTLR-3 agonist and immune cell stimulatorApproved in Other Indications
NCT03673124IIRecurrent low grade serous ovarian cancerA Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or PeritoneumCA, FL, GA, IL, IN, NM, OH, OK, PA, RI, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LetrozoleFemaraAromatase inhibitorNCCN Guidelines for Ovarian Cancer
RibociclibKisqali, CDK4/6 Inhibitor LEE011, LEE011, KisqaliCDK4/6 inhibitorApproved in Other Cancers
NCT03834220IIAdvanced solid tumors with a FGFR1, FGFR2 or FGFR3 fusionA Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3AZ, CA, FL, KY, LA, MD, MA, MI, NJ, NY, NC, OH, OK, TX, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Debiopharm 1347FGFR Inhibitor Debio 1347, FF284, CH5183284, Debio 1347FGFR1-3 inhibitorClinical Trials
NCT03836352IIRecurrent ovarian cancer (with tumor lesions < 5 cm)A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.FL, LA, NY, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
DPX-Survivacsurvivin antigen vaccine DPX-SurvivacImmune response against cancer expressing survivinClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03868423IIAdvanced solid tumors with ALK or ROS1 activating genomic aberrationsPhase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 OncogenesOHView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BrigatinibAP26113ALK and EGFR kinase inhibitorApproved in Other Cancers
NCT03697304IIAdvanced solid tumors with prior PD-1/PD-L1 targeted treatmentAn Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic TherapyCA, FL, IN, KY, OK, TN, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BI 754091anti-PD-1 monoclonal antibody BI 754091Blocks PD-L1/2 inhibition of T cellsClinical Trials
BI 754111Blocks LAG-3 inhibition of T cellsClinical Trials
NCT03878849IIRecurrent ovarian cancerPhase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®MAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
2X-121PARP/Tankyrase inhibitor 2X-121, E7449PARP inhibitorClinical Trials
NCT02819843IIAdvanced solid tumors - intratumoral injectionA Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid TumorsNJ, NYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Radiation TherapyRadiotherapy, Irradiation
Talimogene LaherparepvecGM-CSF-encoding oncolytic herpes simplex virus, T-VECInduces immune response and tumor cell lysisApproved in Other Cancers
NCT03911557IIAdvanced solid tumors with moderate/high TMBPhase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid TumorsKYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cellsClinical Trials
NCT03907475IIAdvanced solid tumors (with tumor amenable to skin biopsy)DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination With Chemotherapy in Patients With Advanced Solid TumorsMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CapecitabineXeloda, CAPERNA processing and thymidylate synthase inhibitorNCCN Guidelines for Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitorApproved in Other Cancers
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitorNCCN Guidelines for Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT03909152IIRecurrent PR+ low grade serous or granulosa cell ovarian cancerBasket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor) in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endometrial CancerNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Onapristone ERextended-release onapristonePR antagonist that blocks PR activation and the associated expression of PR-responsive genes
NCT02710253IIAdvanced solid tumors (amenable to radiation therapy) - with progression on systemic immunotherapyPhase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic ImmunotherapyTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Radiation TherapyRadiotherapy, Irradiation
NCT03449108IIRecurrent high grade serous ovarian cancer or carcinosarcomaClinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinIL-2 receptor agonistApproved in Other Cancers
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
LN-145autologous TILs LN-145, autologous tumor infiltrating lymphocytes LN-145Anti-tumor immune responseClinical Trials
NCT03994796IIAdvanced solid tumors with brain metastases and NTRK, ROS1, CDK pathway or PI3K pathway alterationsGenomically-Guided Treatment Trial in Brain MetastasesAK, AR, CA, CO, ID, IL, IA, KY, LA, MA, MI, MN, MS, MO, MT, NE, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
EntrectinibTrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RXDX-101ALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
GDC-0084RG7666, PI3K inhibitor GDC-0084PI3K/mTOR inhibitor
NCT03993379IIAdvanced solid tumorsA Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid TumorsCA, ID, IL, KY, OR, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CX-072protease-activated anti-PD-L1 antibody prodrug CX-072Blocks PD-L1 inhibition of T cellsClinical Trials
NCT03872427IIAdvanced solid tumors with NF1, KEAP1/NRF2 or LKB1 mutationsA Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant TumorsTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Telaglenastatglutaminase inhibitor CB-839, CD-839Glutaminase inhibitorClinical Trials
NCT04034927IIPlatinum sensitive high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutated ovarian cancerA Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian CancerGA, OH, OK, RIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cellsClinical Trials
NCT04082572IIAdvanced solid tumors with loss of MLH1, PMS2, MSH2 or MSH6 or with high MSINeoadjuvant Pembrolizumab for Patients With Mismatch Repair Deficient Locally Advanced Solid CancersTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04083976IIAdvanced solid tumors with a FGFR mutation or gene fusionA Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene AlterationsAR, CO, CT, FL, GA, ME, MA, NJ, NY, NC, OK, PA, TN, TX, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Erdafitinibpan-FGFR tyrosine kinase inhibitor JNJ-42756493pan-FGFR kinase inhibitorApproved in Other Cancers
NCT04098068IIAdvanced solid tumors with high TMB and low MSIPhase 2 Study of MK-3475 (an Antibody That Blocks Negative Signals to T Cells) in Patients With Microsatellite Unstable (MSI) TumorsMD, MA, NY, OH, OR, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04149275IIRecurrent carcinosarcomaCabozantinib Plus Nivolumab and Ipilimumab Women With Recurrent Gynecologic CarcinosarcomaALView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CabozantinibCometriq, XL184, Cabometyx, BMS-907351Multi-targeted RTK inhibitorApproved in Ovarian Cancer
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04042116Ib/IIAdvanced solid tumors (inc expansion)A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With an Advanced, Metastatic Solid TumorFL, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LucitanibVEGFR/FGFR dual kinase inhibitor E-3810VEGFR and FGFR kinase inhibitorClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03717415Ib/IIAdvanced solid tumorsAn Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid TumorsCA, IL, KS, OH, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
Rebastinibmultitargeted tyrosine kinase inhibitor DCC-2036Multi-targeted kinase inhibitorClinical Trials
NCT02785250Ib/IIRecurrent ovarian cancerA Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian CancerCA, GA, NY, OR, PA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
DPX-Survivacsurvivin antigen vaccine DPX-SurvivacImmune response against cancer expressing survivinClinical Trials
NCT03330405Ib/IIPlatinum sensitive recurrent ovarian cancerA Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid TumorsAR, CA, DC, MA, MI, MN, NY, OH, PA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
TalazoparibTalazoparib Tosylate, BMN-673, MDV3800PARP inhibitorApproved in Other Cancers
NCT02759588Ib/IIPlatinum resistant, refractory or partially sensitive ovarian cancer (with peritoneal disease)Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)CA, FLView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
DocetaxelTaxotereMicrotubule stabilizer/mitotic inhibitorApproved in Other Cancers
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
GL-ONC1light-emitting oncolytic vaccinia virus GL-ONC1, GLV-1h68Membrane disrupterClinical Trials
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitorApproved in Other Cancers
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT02994953IbAdvanced solid tumorsA Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid TumorsCA, CT, FL, LA, MD, MN, MO, OH, OK, OR, SC, TX, VT, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
NHS-IL12M9241, immunocytokine NHS-IL12IL-12 receptor agonistClinical Trials
NCT03113188IbAdvanced solid tumorsPhase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory TumorsAZ, LA, MAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CBP501G2 checkpoint inhibitor CBP501G2 checkpoint inhibitorClinical Trials
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03318445IbAdvanced solid tumors with BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, or RAD54L mutations (inc expansion)Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA RepairCAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IrinotecanCampothecin-11, Campto, CamptosarTopoisomerase I inhibitorNCCN Guidelines for Ovarian Cancer
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitorApproved in Ovarian Cancer
NCT03150810IbAdvanced solid tumors (inc ovarian expansion)A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid TumorsMI, MO, NY, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PamiparibPARP inhibitor BGB-290PARP inhibitorClinical Trials
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agentApproved in Other Cancers
NCT03206177IbNewly diagnosed, persistent, or recurrent ovarian carcinosarcomaFeasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or OvaryOKView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
GalunisertibLY2157299TGFBR1 antagonistClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT02761694IbAdvanced solid tumors with AKT1/2/3, PI3K, or PTEN mutations (in expansion)A Phase 1b Study of ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents in Adult Subjects With Advanced Solid Tumors With PIK3CA / AKT / PTEN MutationsOK, SC, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ARQ 751pan-AKT inhibitor ARQ 751Akt inhibitorClinical Trials
FulvestrantFaslodex, ICI 182,780, ZD9238ER antagonist (SERD)Approved in Other Cancers
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT03695380IbPlatinum sensitive ovarian cancer with ≤ 2 prior platinum therapies (inc expansion)A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian CancerAZ, CA, FL, GA, MD, MO, NY, OK, TN, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
CobimetinibXL518, GDC-0973, CotellicMEK1 inhibitorApproved in Other Cancers
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
NCT03650348IbAdvanced HER2+ solid tumors (inc expansion)A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid TumorsCA, LA, NY, OH, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
PRS-343anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343Immune response against cancer expressing HER2Clinical Trials
NCT03589651IbAdvanced solid tumors (inc expansion)A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid TumorsCA, CT, FL, IL, NJ, NY, PA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
EpacadostatIDO1 Inhibitor INCB024360, INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, 3-dioxygenase Inhibitor INCB024360Inhibits IDO1 to stimulate immune responseClinical Trials
MGA012anti-PD-1 monoclonal antibody MGA012, INCMGA00012Blocks PD-L1 inhibition of T cellsClinical Trials
ParsaclisibPI3K-delta inhibitor INCB050465, INCB050465PI3K delta inhibitorClinical Trials
NCT03842228IbAdvanced solid tumors (inc expansion)A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid TumorsTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitorClinical Trials
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03872947IbPlatinum sensitive or partially sensitive ovarian cancerA Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid TumorsAZ, CA, LA, NJ, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
TRK-950monoclonal antibody TRK-950Undisclosed mechanismClinical Trials
NCT03514121Ia/IbAdvanced solid tumors (in ovarian expansion)A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid TumorsAZ, CA, CT, IL, MI, OK, TN, TX, UT, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
FPA150anti-B7-H4 monoclonal antibody FPA150Blocks B7-H4 inhibition of T cellsClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03209401Ia/IbAdvanced solid tumors with mutations in ARID1A, ATM, ATRX, MRE11A, NBN, PTEN, RAD50/51/51B, BARD1, BLM, BRCA1/2, BRIP1, FANCA/C/D2/E/F/G/L, PALB2, WRN, CHEK2, CHEK1, BAP1, FAM175A, SLX4, MLL2 or XRCC (inc expansion)Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor MalignanciesDCView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
NCT02913313I/IIaAdvanced solid tumorsPhase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid TumorsPA, UTView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986207anti-TIGIT monoclonal antibody BMS-986207Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cellsClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT02754141I/IIaAdvanced solid tumorsA Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid TumorsCT, IL, MD, MA, NY, OK, PA, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986179anti-CD73 monoclonal antibody BMS-986179Blocks Ecto-5-nucleotidase (CD73) inhibition of T cellsClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03110107I/IIaAdvanced solid tumors (in expansion)Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid TumorsCO, MA, NV, NJ, NY, PAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986218Blocks CTLA-4 inhibition of T cellsClinical Trials
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT02650986I/IIaAdvanced solid tumors (inc expansion)A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced MalignanciesNYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
NY-ESO-1 reactive TCR retroviral vector transduced autologous PBLanti-NY-ESO-1 TCR gene-engineered lymphocytesImmune response against cancer expressing NY-ESO-1Clinical Trials
TGFbeta DNRII-transduced Autologous Tumor Infiltrating LymphocytesTGFbeta Dominant Negative Receptor II transduced TILSTGFbeta ligand trapClinical Trials
NCT02111850I/IIAdvanced MAGE-3+ solid tumorsPhase I/II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and AldesleukinMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinIL-2 receptor agonistApproved in Other Cancers
Anti-MAGE-A3-DP4 TCR PBLHLA-DP0401/0402-restricted, MAGE-A3-reactive T cell receptor-transduced autologous T cellsImmune response against cancer expressing MAGE-3Clinical Trials
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
NCT02953457I/IIRecurrent, persistent or refractory high grade serous ovarian cancer with BRCA1/2 or HRD or MMR gene alterations or high LOH/HRD scoresA Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 MutationNYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cellsClinical Trials
NCT02432378I/IIPlatinum sensitive ovarian cancer with first recurrence in peritoneal cavity - intranodal injection (inc expansion)A Phase 1-2 Neoadjuvant Dose Finding, Safety, and Immunologic Efficacy Trial of Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer and Tumor-Specific Intranodal Autologous Alpha-DC1 VaccinesPAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Alpha-DC1 vaccineAnti-tumor immune responseClinical Trials
CelecoxibCelebrexApproved in Other Indications
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
NCT02671435I/IIAdvanced solid tumorsA Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid TumorsAL, AZ, CA, CO, FL, IL, MD, MA, MI, NJ, NY, PA, RI, TN, TX, UT, WAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
MonalizumabIPH2201, anti-NKG2A monoclonal antibody IPH2201Blocks HLA-E inhibition of NKG2A+ NK and cytotoxic T-lymphocytesClinical Trials
NCT02484404I/IIRecurrent ovarian cancerPhase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal CancersMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CediranibAZD2171, Cediranib maleate, RecentinVEGFR1-3 kinase inhibitorClinical Trials
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT02487095I/IIExtrapulmonary small cell ovarian cancerA Phase I/II Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell CancersMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BerzosertibATR kinase inhibitor VX-970, VE-822, M6620, VX-970ATR kinase inhibitorClinical Trials
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitorApproved in Ovarian Cancer
NCT02734004I/IIPlatinum sensitive recurrent ovarian cancerA Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid TumorsGA, MD, MA, MI, MO, OH, PA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03251924I/IIAdvanced solid tumors (inc expansion)A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid TumorsDC, MA, MO, NJ, PA, TNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986226anti-ICOS BMS-986226, anti-inducible T-cell co-stimulator BMS-986226Stimulates ICOS to increase T cell activity and immune responseClinical Trials
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03369223I/IIAdvanced solid tumorsA Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid TumorsCO, FL, MD, NJ, NY, OH, OR, PA, SC, TX, VA, WAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986249Probody of ipilumumabBlocks CTLA-4 inhibition of T cellsClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03314935I/IIAdvanced solid tumors (inc expansion)A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid TumorsAL, CA, GA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
INCB001158CB-1158, Arginase inhibitorArginase inhibitorClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT03446040I/IIAdvanced solid tumorsA Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant TumorsCA, CO, CT, MI, NH, PA, TNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986258anti-TIM3 antibody BMS-986258Blocks TIM-3 inhibition of T cellsClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03386526I/IIAdvanced solid tumorsA Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as A Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic MalignanciesTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
APG-138SMAC mimetic and IAP antagonistClinical Trials
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03400332I/IIAdvanced solid tumorsA Phase 1/2a Study of BMS-986253 in Combination With Nivolumab in Advanced CancersCO, FL, MD, NV, NJ, NY, OK, OR, PA, SC, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986253HuMax-IL8, anti-IL-8 monoclonal antibody HuMax-IL8, MDX 018IL-8 antagonistClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03459222I/IIAdvanced solid tumorsA Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant TumorsCA, CO, MD, MO, TN, WAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986205Inhibits IDO1 to stimulate immune responseClinical Trials
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RelatlimabBMS986016, Anti-LAG-3 monoclonal antibody BMS-986016, Anti-LAG-3 monoclonal antibody BMS-986016Blocks LAG-3 inhibition of T cellsClinical Trials
NCT03721679I/IIAdvanced solid cancersPoly-ICLC (Hiltonol®) Plus Anti-PD1 or Anti-PD-L1 in Unresectable Solid Cancers An Adaptive Phase I/II Clinical Pilot StudyMD, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
CemiplimabREGN2810, anti-PD-1 monoclonal antibody REGN2810Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
poly ICLCpoly-ICLC, Hiltonol, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, poly I:poly C with poly-1-lysine stabilizerActivates dendritic cells and induces interferon productionClinical Trials
NCT03775850I/IIAdvanced MSI-high solid tumors that relapsed following PD-1/L-1 checkpoint inhibitor therapyA Phase I/II Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed TumorsFL, OK, TNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
EDP1503monoclonal microbial EDP1503Clinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03761914I/IIRecurrent or persistent WT1+ ovarian cancerA Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced CancersCA, FL, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Galinpepimut-SImmune response against cancer expressing WT1Clinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03744468I/IIAdvanced solid tumorsPhase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid TumorsCO, PAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BGB-A425Blocks TIM-3 inhibition of T cellsClinical Trials
Tislelizumabanti-PD-1 monoclonal antibody BGB-A317Blocks PD-L1/2 inhibition of T cellsClinical Trials
NCT03767348I/IIAdvanced solid tumor - intratumoral injection (in expansion)An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid TumorsAL, AZ, CT, FL, IA, KY, NJ, NY, OR, TN, TX, UT, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RP1oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virusInduces immune response and tumor cell lysisClinical Trials
NCT03157128I/IIAdvanced solid tumorsA Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)AZ, CA, CO, CT, FL, GA, IL, LA, MD, MA, MI, MN, MO, NV, NY, NC, OH, OR, PA, TN, TX, UT, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
SelpercatinibRET kinase inhibitor LOXO-292, LOXO-292RET-kinase inhibitorClinical Trials
NCT03665285I/IIRecurrent ovarian cancerA Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid TumorsCA, CT, NJ, NY, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NC318anti-S15 monoclonal antibody NC318, anti-Siglec-15 monoclonal antibody NC318Blocks tumor-associated macrophage stimulation of tumor growthClinical Trials
NCT03907852I/IIAdvanced mesothelin+ solid tumors (inc ovarian expansion)A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing CancerMD, PA, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
TC-210 T cellsTC-210 TruC-T cellsImmune response against cancer expressing mesothelinClinical Trials
NCT03840200I/IIRecurrent ovarian cancerA Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate CancerCA, PA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpatasertibGDC-0068, Akt Inhibitor GDC-0068, RG7440pan-AKT inhibitorClinical Trials
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitorApproved in Ovarian Cancer
NCT03729596I/IIAdvanced solid tumorsA Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid TumorsMI, NC, VAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MGA012anti-PD-1 monoclonal antibody MGA012, INCMGA00012Blocks PD-L1 inhibition of T cellsClinical Trials
MGC018A humanized anti-B7-H3 antibody conjugated to the vc- seco - DUocarmycin-hydroxyBenzamide-Azaindole (DUBA) 2 DNA alkylating payloadADC: anti-B7-H3 + DNA alkylating agent (duocarmycin)Clinical Trials
NCT04068194I/IIAdvanced solid tumorsA Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary MalignanciesContact NCIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
NedisertibDNA-PK inhibitor MSC2490484A, M3814DNA-PK inhibitorClinical Trials
Radiation TherapyRadiotherapy, Irradiation
NCT04021043I/IIAdvanced solid tumors (inc expansion)Phase I/II Trial of Ipilimumab or Nivolumab With BMS-986156 and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid MalignanciesTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986156GITR (glucocorticoid-induced TNFR) agonistClinical Trials
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyRadiotherapy, Irradiation
NCT03997968I/IIAdvanced solid tumors (inc expansion)A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid TumorsCO, TNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CYT-0851RAD51 inhibitor
NCT03992131I/IIAdvanced solid tumors (inc ovarian expansion)SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid TumorMA, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LucitanibVEGFR/FGFR dual kinase inhibitor E-3810VEGFR and FGFR kinase inhibitorClinical Trials
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitorApproved in Ovarian Cancer
Sacituzumab Govitecananti-TROP-2 Antibody-Drug Conjugate IMMU-132, hrS7-SN38 antibody drug conjugateADC: Anti-TROP2 + topoisomerase I inhibitorClinical Trials
NCT03994601I/IIAdvanced solid tumors (inc expansion)A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Malignant TumorsCO, MD, MO, NJView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986288Undisclosed mechanismClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03600883I/IIAdvanced solid tumors with KRAS G12C mutation (inc expansion)A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreakTM 100)CA, CO, CT, GA, IN, MA, MI, MO, NY, NC, PA, SC, TN, TX, UT, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AMG 510KRAS mutant-targeting AMG 510KRAS G12C inhibitorClinical Trials
NCT03297424I/IIAdvanced solid tumors (inc ovarian expansion)A Phase 1b/2a Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Advanced MalignanciesAZ, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PLX2853BRD4 inhibitor PLX2853BRD4 inhibitor
NCT04165330I/IIAdvanced solid tumorsA Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818 (Catequentinib) to Nivolumab in Solid TumorsCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AnlotinibAL3818, CatequentinibVEGFR2/3 kinase inhibitorClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04165031I/IIAdvanced solid tumors (inc expansion)A Phase 1/2 Study of LY3499446 Administered to Patients With Advanced Solid Tumors With KRAS G12C MutationCA, IN, MA, NH, NJ, NY, NC, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
CetuximabErbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225EGFR antagonistApproved in Other Cancers
DocetaxelTaxotereMicrotubule stabilizer/mitotic inhibitorApproved in Other Cancers
ErlotinibTarcevaEGFR kinase inhibitor
LY3499446KRAS G12C inhibitor
NCT03138083I/IIAdvanced solid tumors with MET alterationsA Modular, Multi-arm, Multi-part, First Time in Patient Study to Evaluate the Safety and Tolerability of OMO-1, Alone and in Combination With Anti-cancer Treatments, in Patients With Locally Advanced, Unresectable or Metastatic Solid MalignanciesTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OMO-1JNJ-38877618, MET kinase inhibitor OMO-1c-Met kinase inhibitor
NCT04104776I/IIAdvanced solid tumors (inc expansion)A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination With Other Therapy in Patients With Advanced Solid TumorsMI, NJ, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CPI-0209EZH2 histone methyltransferase inhibitor
IrinotecanCampothecin-11, Campto, CamptosarTopoisomerase I inhibitorNCCN Guidelines for Ovarian Cancer
NCT03711058I/IIAdvanced solid tumors with low MSIA Phase I/II Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal CancerMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitorClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03785249I/IIAdvanced solid tumors with KRAS G12C mutation (inc expansion)A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C MutationCA, CO, MA, MI, NY, NC, TN, TX, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MRTX849KRAS G12C inhibitor MRTX849KRAS G12C inhibitorClinical Trials
NCT04143711I/IIAdvanced HER2+ solid tumors (inc expansion)A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected IndicationsTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DF1001Activates NK cells to stimulate immune response
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03907969I/IIAdvanced solid tumors (inc expansion)A Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination With Either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients With Advanced MalignanciesCT, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AZD7648DNA-PK inhibitor
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitorApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03884556I/IbAdvanced solid tumors (inc expansion)Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor MalignanciesFL, TN, TX, UTView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DocetaxelTaxotereMicrotubule stabilizer/mitotic inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
TTX-030anti-CD39 monoclonal antibodyInhibits the breakdown of ATP by CD39Clinical Trials
NCT02660034I/IbPlatinum sensitive or partially sensitive ovarian cancer (at least 2 prior platinum therapies, in expansion)A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid TumorsAZ, CA, CO, FL, MA, TN, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PamiparibPARP inhibitor BGB-290PARP inhibitorClinical Trials
Tislelizumabanti-PD-1 monoclonal antibody BGB-A317Blocks PD-L1/2 inhibition of T cellsClinical Trials
NCT03511222IAdvanced solid tumors with high MSIA Phase IB Trial of Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid TumorsMOView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
VorolanibCM-082, X-82VEGFR and PDGFR kinase inhibitorClinical Trials
NCT01417546IAdvanced solid tumors (in expansion)First In-Human Phase I Trial of NHS-IL12 in Patients With Metastatic Solid TumorsMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NHS-IL12M9241, immunocytokine NHS-IL12IL-12 receptor agonistClinical Trials
NCT03435250IAdvanced solid tumors with CDKN2A deletion (inc expansion)A Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors or Lymphoma With Homozygous Deletion of MTAPCT, MA, NY, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AG-270Methionine adenosyltransferase 2a (MAT2A) inhibitorClinical Trials
NCT03538028IAdvanced solid tumors (inc expansion)A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced MalignanciesCA, NJ, NC, TNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
INCAGN02385Blocks LAG-3 inhibition of T cellsClinical Trials
NCT03517956IAdvanced solid tumors with FGFR over-expressionA Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients With FGFR-positive, Locally Advanced or Metastatic Solid TumorsCA, IL, MD, MA, MI, NV, NY, SC, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitorClinical Trials
Rogaratinibpan-FGFR tyrosine kinase inhibitor BAY1163877, BAY1163877pan-FGFR kinase inhibitorClinical Trials
NCT03255070IAdvanced HER+ solid tumorsA Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 ExpressionMOView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ARX788anti-HER2 antibody-drug conjugate ARX788, ADC ARX788ADC: anti-HER2 + microtubule destabilizer (MMAF)Clinical Trials
NCT03330561IAdvanced HER2+ solid tumors (inc expansion)A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid TumorsAZ, CA, DC, MD, NY, PA, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PRS-343anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343Immune response against cancer expressing HER2Clinical Trials
NCT03059823IAdvanced solid tumors (inc expansion)A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid TumorsAZ, MI, NJ, NC, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MGA012anti-PD-1 monoclonal antibody MGA012, INCMGA00012Blocks PD-L1 inhibition of T cellsClinical Trials
NCT03431948IAdvanced solid tumors (amenable to radiation therapy)Platform Phase 1 Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid TumorsILView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Cabiralizumabanti-CSF1R monoclonal antibody FPA008, FPA008CSF1R antagonist and tumor-associated macrophage inhibitorClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyRadiotherapy, Irradiation
UrelumabBMS-663513, anti-CD137 monoclonal antibody, anti-4-1BB monoclonal antibodyStimulates 4-1BB (CD137) to increase T cells and immune responseClinical Trials
NCT03335540IAdvanced solid tumorsADaptiVe Biomarker Trial That InformS Evolution of TherapyIL, MD, PAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986205Inhibits IDO1 to stimulate immune responseClinical Trials
Cabiralizumabanti-CSF1R monoclonal antibody FPA008, FPA008CSF1R antagonist and tumor-associated macrophage inhibitorClinical Trials
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RelatlimabBMS986016, Anti-LAG-3 monoclonal antibody BMS-986016, Anti-LAG-3 monoclonal antibody BMS-986016Blocks LAG-3 inhibition of T cellsClinical Trials
NCT02675439IAdvanced solid tumors - intratumoral injectionA Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or LymphomasCO, IL, MA, NY, TX, UTView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ADU-S100CDN agonist ADU-S100, MIW815, STING-activating cyclic dinucleotide agonist ADU-S100Activates STING to stimulate immune cell activationClinical Trials
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NCT03144661IRecurrent advanced serous ovarian cancerA Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other MalignanciesAL, NYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
INCB062079FGFR4 inhibitorClinical Trials
NCT03154294IAdvanced solid tumorsA Phase 1 Evaluation of the Safety and Tolerability of TAK-228 in Combination With TAK-117 and Paclitaxel in Advanced Solid TumorsSDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
SapanisertibINK128, TORC1/2 Inhibitor INK128, TORC1/2 Inhibitor MLN0128, MLN0128, TAK-228TORC1/2 kinase inhibitorClinical Trials
SerabelisibPI3K alpha inhibitor MLN1117, TAK-117, INK-1117, MLN1117PI3K alpha inhibitorClinical Trials
NCT03213964IRecurrent advanced ovarian cancer only in abdomen/pelvisIntraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Interleukin-2 in Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerMNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
FATE-NK100NKG2C/CD57-expressing adaptive memory natural killer cells FATE-NK100Anti-tumor immune responseClinical Trials
NCT03319459IAdvanced solid tumors, including HER2+ or EGFR+ tumorsFATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid TumorsCA, MN, OH, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CetuximabErbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225EGFR antagonistApproved in Other Cancers
FATE-NK100NKG2C/CD57-expressing adaptive memory natural killer cells FATE-NK100Anti-tumor immune responseClinical Trials
TrastuzumabHerceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal AntibodyHER2 antagonistApproved in Other Cancers
NCT02937272IAdvanced solid tumors (inc expansion)A Phase 1 Study of LY3200882 in Patients With Solid TumorsKY, NY, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
LodapolimabLY3300054Blocks PD-L1 inhibition of T cellsClinical Trials
LY3200882TGFbeta inhibitor LY3200882, TGFb inhibitor LY 3200882TGFbeta antagonistClinical Trials
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitorNCCN Guidelines for Ovarian Cancer
NCT03289962IAdvanced solid tumorsA Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic TumorsAZ, CA, CO, CT, DC, MA, NV, NY, OK, OR, TN, WAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
RO7198457personalized cancer vaccine RO7198457, PCV RO7198457Immune response against tumor-associated antigensClinical Trials
NCT03229278IAdvanced solid tumors with high MSIA Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking AntibodiesNJView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
TrigriluzoleBHV-4157, FC-4157Glutamate antagonistClinical Trials
NCT03310541IAdvanced solid tumors with AKT1, AKT2, or AKT3 mutationsA Pilot Study of AZD5363 for Patients With Advanced Solid Tumors Harboring Mutations in AKT1, AKT2, or AKT3NJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CapivasertibAkt inhibitor AZD5363, AZD5363pan-AKT inhibitorClinical Trials
NCT02715284IAdvanced solid tumors (inc expansion)A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid TumorsAL, AZ, AR, CA, DC, FL, GA, IL, KS, ME, MA, MI, MO, NM, NY, NC, OH, OK, OR, PA, RI, TN, TX, UT, VA, WA, WV, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DostarlimabANB011, anti-PD-1 monoclonal antibody TSR-042, TSR-042Blocks PD-L1/2 inhibition of T cellsClinical Trials
NCT03313778IAdvanced solid tumors with high MSI or high TMB (in expansion)A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid TumorsFL, MA, NJ, NY, NC, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
mRNA-4157mRNA-based personalized cancer vaccine mRNA-4157Anti-tumor immune responseClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT01434316IAdvanced solid tumors including those with BRCA1/2 mutations (in expansion)Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid TumorsMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DinaciclibCDK inhibitor SCH 727965, SCH 727965CDK1, 2, 5, 9 inhibitorClinical Trials
VeliparibABT-888PARP inhibitorClinical Trials
NCT02503774IAdvanced solid tumors (in expansion)A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid TumorsCA, CT, FL, GA, MO, NC, OH, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
Oleclumabanti-CD73 monoclonal antibody MEDI9447Blocks Ecto-5-nucleotidase (CD73) inhibition of T cellsClinical Trials
NCT02627443IPlatinum sensitive ovarian cancer at first or second recurrencePhase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube CancerAZ, CO, FL, KY, MI, MN, MO, PA, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BerzosertibATR kinase inhibitor VX-970, VE-822, M6620, VX-970ATR kinase inhibitorClinical Trials
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
NCT02433626IRecurrent ovarian cancerA Phase 1 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Advanced or Recurrent MalignanciesTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
COTI-2mutant p53 activator COTI-2Mutant p53 activatorClinical Trials
NCT02534922IRecurrent or persistent ovarian cancerPhase I Open-Label, Dose-Escalation and Pharmacokinetic Study of Subcutaneous Prolanta™ in Subjects With Recurrent or Persistent Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerSCView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ProlantaProlactin receptor antagonistClinical Trials
NCT02791334IAdvanced solid tumors (in expansion)A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LodapolimabLY3300054Blocks PD-L1 inhibition of T cellsClinical Trials
LY3321367anti-TIM3 monoclonal antibody LY3321367Blocks TIM-3 inhibition of T cellsClinical Trials
Ramucirumabanti-VEGFR-2 fully human monoclonal antibody IMC-1121B, IMC-1121B, LY3009806VEGFR2 antagonistApproved in Other Cancers
NCT02897375IAdvanced solid tumorsA Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid MalignanciesGAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitorApproved in Other Cancers
NCT01376505IAdvanced solid tumors (in ovarian expansion)Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid TumorsOHView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MVF-HER-2(597-626)-MVF-HER-2 (266-296) peptide vaccineB-VaxxImmune response against cancer expressing HER2Clinical Trials
NCT02498912IMUC16+ recurrent high grade serous ovarian cancer (> 2 prior therapies)A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid TumorsNYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
4H11-28z/fIL-12/EFGRt-expressing autologous T lymphocytes4H11-28z/fIL-12/EFGRt+ genetically-modified T cells, autologous MUC16ecto-targeting EGFR-secreting T lymphocytesImmune response against cancer expressing CA125Clinical Trials
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
NCT02829723IAdvanced solid tumorsA Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid TumorsTN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BLZ945CSF-1R inhibitor BLZ945CSF1R antagonist and tumor-associated macrophage inhibitorClinical Trials
Spartalizumabanti-PD-1 monoclonal antibody PDR001, PDR001Blocks PD-L1/2 inhibition of T cellsClinical Trials
NCT03017131IRecurrent or refractory ovarian cancerA Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination With Decitabine in Patients With Recurrent or Treatment Refractory Ovarian CancerNYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
Decitabine5-aza-dCyd, deoxyazacytidine, dezocitidine, DacogenDNA methylation inhibitorApproved in Other Cancers
Genetically Engineered NY-ESO-1-specific T LymphocytesImmune response against cancer expressing NY-ESO-1Clinical Trials
NCT03030378IAdvanced solid tumorsA Phase 1 Study of MK-3475 (Pembrolizumab) in Combination With Recombinant Interleukin-12 in Patients With Solid TumorsCA, CO, CT, FL, GA, MD, MA, MO, NJ, NC, OH, PA, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IL-12cytotoxic lymphocyte maturation factor interleukin-12, Ro 24-7472, recombinant interleukin-12, natural killer cell stimulatory factor NM-IL-12IL-12 receptor agonist
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT02972034IAdvanced solid tumorsA Phase Ib Study to Evaluate the Safety and Tolerability of MK-8353 in Combination With Pembrolizumab in Patients With Advanced MalignanciesMI, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MK-8353ERK1 inhibitor MK-8353ERK inhibitorClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03056833IPlatinum sensitive recurrent ovarian cancerPhase I Trial of Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
RibociclibKisqali, CDK4/6 Inhibitor LEE011, LEE011, KisqaliCDK4/6 inhibitorApproved in Other Cancers
NCT03023319IAdvanced solid tumorsPhase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid TumorsGAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BosutinibBosulif, SKI-606Abl and src family kinase inhibitorApproved in Other Cancers
PemetrexedPemetrexed disodium, AlimtaDHFR and Thymidylate synthase inhibitorNCCN Guidelines for Ovarian Cancer
NCT03069469IAdvanced solid tumors (in expansion)Multi-center, Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced TumorsCA, CO, FL, NY, OR, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DCC-3014CSF1R kinase inhibitorClinical Trials
NCT03018405IAdvanced solid tumors (in expansion)A Multi-national, Open-label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types (THINK - THerapeutic Immunotherapy With NKR-2)FL, NYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NKR-2autologous NKG2D CAR-CD3zeta-DAP10-expressing T lymphocytes CYAD-01Immune response against cancer expressing NKG2D-LClinical Trials
NCT03054298IRecurrent or persistent mesothelin+ serous ovarian cancerPhase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing CancersPAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
Hu-CART-meso cellsImmune response against cancer expressing mesothelinClinical Trials
NCT03154281IAdvanced ovarian cancer (no prior PARPi)A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination With Everolimus in Advanced Ovarian and Breast CancerSDView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
EverolimusAfinitor, Certican, RAD001, ZortressmTOR inhibitorApproved in Other Cancers
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
NCT02611024IAdvanced solid tumors (inc expansion)Phase I, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid TumorsMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IrinotecanCampothecin-11, Campto, CamptosarTopoisomerase I inhibitorNCCN Guidelines for Ovarian Cancer
LurbinectedinPM01183DNA damaging agentClinical Trials
NCT03192345IAdvanced solid tumorsA Phase 1/1b First-in-human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With Cemiplimab in Adult Patients With Advanced Solid TumorsCA, KS, MA, NC, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CemiplimabREGN2810, anti-PD-1 monoclonal antibody REGN2810Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
SAR439459anti-TGF-beta monoclonal antibody SAR-439459TGFbeta antagonistClinical Trials
NCT03894540IAdvanced solid tumors (inc expansion)A Phase I, Open Label, Dose Escalation and Dose Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumour Activity of IPN60090 as Single Agent and in Combination in Patients With Advanced Solid TumoursTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IPN60090Undisclosed mechanismClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03893955IAdvanced solid tumorsA Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid TumorsAL, CA, CT, NC, TX, VAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ABBV-368Stimulates OX40 to increase T cell activation and immune responseClinical Trials
ABBV-927anti-CD40 agonist monoclonal antibody ABBV-927Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune responseClinical Trials
NCT03875287IAdvanced solid tumorsA Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Subjects With Solid TumorsMDView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ASTX727CDA inhibitor E7727/decitabine combination agent ASTX727DNA methylation inhibitorClinical Trials
NCT03156114IAdvanced solid tumors with high MSI or high TMB and prior checkpoint inhibitor treatment (in expansion)An Open Label, Phase I Dose-finding Study of BI 754111 in Combination With BI 754091 in Patients With Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients With Non-small Cell Lung Cancer and Other Solid TumorsFL, NJ, OK, TN, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BI 754091anti-PD-1 monoclonal antibody BI 754091Blocks PD-L1/2 inhibition of T cellsClinical Trials
BI 754111Blocks LAG-3 inhibition of T cellsClinical Trials
NCT02990481IAdvanced solid tumors (in expansion)A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of TRK-950 Given Intravenously in Patients With Advanced Solid TumorsAZView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TRK-950monoclonal antibody TRK-950Undisclosed mechanismClinical Trials
NCT03841110IAdvanced solid tumors (inc expansion)FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)CA, MN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
FT500Anti-tumor immune responseClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03849469IAdvanced solid tumors (inc expansion)A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)GA, MI, TX, UTView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
XmAb22841anti-CTLA-4/LAG-3 bispecific antibody XmAb22841Blocks LAG-3 and CTLA-4 inhibition of T cellsClinical Trials
NCT03861793IAdvanced solid tumors (inc expansion)A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-2 (001)DC, GA, MI, NY, NC, PA